Assess whether a CMO finding is a delay or a refuse-to-file risk (c51370)

Situation

RWE protocol that may not meet regulator expectations arrived with an inspector asking for batch records you cannot produce this week for clinical-development physician. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on a CMO finding is in a biologics company planning a biosimilar pathway.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize A CMO finding is a delay now; RWE protocol that may not meet regulator expectations already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep A refuse-to-file risk in force until RWE protocol that may not meet regulator expectations is completed after an inspector asking for batch records you cannot produce this week for clinical-development physician.
• Treat RWE protocol that may not meet regulator expectations as A CMO finding is a delay because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page a CMO finding is turns on in RWE protocol that may not meet regulator expectations.

Analysis required

• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.